Pfizer
is set to report its earnings on Tuesday, a week and a 50 % soon after an govt explained to investors that the corporation was considering a listing price tag for its Covid-19 vaccine of among $110 and $130 per grownup dose, larger than analysts experienced expected.
The surprise has led analysts to rethink their estimates for future year’s Covid-19 vaccine profits, and raised questions about how to feel about
Pfizer
extensive-expression prospective customers. The firm will have an chance to handle people challenges at an investor simply call scheduled for 10 a.m. on Tuesday. Fiscal benefits for the company’s third quarter will come just before the marketplace opens.
Pfizer
is set to report its earnings on Tuesday, a week and a 50 % soon after an govt explained to investors that the corporation was considering a listing price tag for its Covid-19 vaccine of among $110 and $130 per grownup dose, larger than analysts experienced expected.
The surprise has led analysts to rethink their estimates for future year’s Covid-19 vaccine profits, and raised questions about how to feel about
Pfizer
extensive-expression prospective customers. The firm will have an chance to handle people challenges at an investor simply call scheduled for 10 a.m. on Tuesday. Fiscal benefits for the company’s third quarter will come just before the marketplace opens.
